Dr. Weeks’ Comment: Real Hormone Therapy (RHT) – the use of bio-identical hormones (just like the ones you used to make!) makes sense … it is “centsible” (safe, effective and cost-effective). In contrast, medical practice is dishonored by Big Pharma foisting non-bioidentical hormones on trusting patients and causing death and stroke. The most recent example is PremPro ® a drug made from horse estrogen (too powerful for and not well-metabolized by humans) and Premarin ® – a progestin and NOT a synthetic progesterone – but actually a bioengineered progesterone-like molecule (progestin) which is a “near miss” a “knock off” of the natural beneficial progesterone. Progestin differs significantly enough from bio-identical progesterone that it can be patented and profitable. ( The law suits were huge. ) The tragic and misguided use of hormone blockers, like androgen blockade, as part of the accepted standard of care for prostate cancer has caused tremendous suffering and led to the untimely death of tens of thousands of trusting men. Increasingly, androgen blockage is discredited– the science never supported it – but it was profitable. In fact, the role of testosterone and prostate cancer is a matter of great debate.
Now, the work of maligned (but scientifically rigorous) doctors who use bio-identical “centsible” hormones is being noticed. And appreciated. We now know that low testosterone is the risk for prostate cancer. This is the direct opposite of what conventional oncologists have preached. More shocking, rather than reduce testosterone in men with prostate cancer, Harvard’s Abraham Morgentaler, M.D. actually GIVES TESTOSTERONE to these men and prostate cancer goes away. He clarifies the risk here.
AND NOW ….
Dr. Rebecca Glaser is preventing and curing breast cancer by giving women….. testosterone!
Here are some articles to consider.
- Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
2014 Jun;21(6):673-8. doi: 10.1097
This novel therapy, delivered in the neoadjuvant setting, has the potential to identify early responders and to evaluate the effectiveness of therapy in vivo. This may prove to be a new approach to both local and systemic therapies for breast cancer in subgroups of patients. In addition, it can be used to reduce tumor volume, allowing for less surgical intervention and better cosmetic oncoplastic results.
- Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
2013 Dec;76(4):342-9. doi: 10.1016/j.maturitas.2013.08.002. Epub 2013 Sep 10.
T and/or T+A, delivered subcutaneously as a pellet implant, reduced the incidence of breast cancer in pre and postmenopausal women. Evidence supports that breast cancer is preventable by maintaining a T to estrogen ratio in favor of T and, in particular, by the use of continuous T or, when indicated, T+A. This hormone therapy should be further investigated for the prevention and treatment of breast cancer.
2013 Feb 1. pii: S0378-5122(13)00012-1. doi: 10.1016/j.maturitas.2013.01.003. [Epub ahead of print]
Although testosterone therapy is being increasingly prescribed for men, there remain many questions and concerns about testosterone (T) and in particular, T therapy in women. A literature search was performed to elucidate the origin of, and scientific basis behind many of the concerns and assumptions about T and T therapy in women. This paper refutes 10 common myths and misconceptions, and provides evidence to support what is physiologically plausible and scientifically evident: T is the most abundant biologically active female hormone, T is essential for physical and mental health in women, T is not masculinizing, T does not cause hoarseness, T increases scalp hair growth, T is cardiac protective, parenteral T does not adversely affect the liver or increase clotting factors, T is mood stabilizing and does not increase aggression, T is breast protective, and the safety of T therapy in women is under research and being established. Abandoning myths, misconceptions and unfounded concerns about T and T therapy in women will enable physicians to provide evidenced based recommendations and appropriate therapy.